Mission Statement
Research conducted by external investigators within therapeutic areas of interest to Cytokinetics can provide valuable information to help us better understand disease states and may help improve the healthspan of patients. We are proud to actively support both clinical and non-clinical (pre-clinical) research through our Investigator-Initiated Research (IIR) Program.
Program Governance
The IIR program is designed with robust medical and scientific governance in place at all levels of Cytokinetics with no influence from commercial, marketing, or sales in any stage of the process. Under no circumstances will we permit the involvement of sales and marketing associates in any aspect of IIR design, review and approval, operational execution, funding or transfer of value to a sponsor/investigator undertaking an IIR.
Areas of Interest for Clinical IIR Submissions
To provide guidance on strategic and research priorities, Cytokinetics has developed Areas of Interest, which are regularly reviewed and revised to reflect the changing landscape of the therapeutic space. These Areas of Interest serve as guidance, however, to avoid restricting scientific creativity, proposals not aligned with Areas of Interest will also be considered. Adherence to the Areas of Interest does not guarantee approval from the review committee.
Areas of Interest not requiring study medication:
- Unmet needs in obstructive HCM: etiology, diagnosis, epidemiology, clinical and health economic outcome measures, underserved populations, quality of life, and health equity assessments
- Innovative approaches to monitoring disease progression and treatment impact
- Disease remodeling in HCM
- Other research focus areas will be considered so as not to restrict scientific creativity
Please note that for clinical submissions we are only considering funding requests at this time – drug and in-kind support are not currently available.
Note: Compassionate-use requests are out-of-scope for the IIR program. For more information, please read our Access Policy.